Skip to main content

Table 1 Enrolled patients characteristics

From: Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Study group

 

Patients

Breast cancer

Adenocarcinoma

20

47,5

Median age (range)

 

(32–69)

Clinical status

IIA

1

IIB

3

IIIA

12

IIIB

3

IIIC

1

Histologic grade

1

1

2

8

3

11

HER2 status

positive

9

negative

11

ER status

positive

11

negative

8

unknown

1

PR status

positive

13

negative

7